Sanofi-Aventis Sees India As Major Site For Diabetes Treatments
This article was originally published in PharmAsia News
Executive Summary
France's Sanofi-Aventis sees India as a possible base for the company's global effort to be a major player in diabetes treatments. In addition to beginning research into India-specific drug combinations and marketing of its Apidra (glulisine recombinant) insulin in India later this year, the firm also may make the country a global hub for its insulin manufacturing. The French drug maker already has a 7.9 percent market share for oral diabetes drugs and insulin through its Indian arm, Aventis Pharma. The subsidiary relies on a large Indian market for combination drugs, spurring the move to India-specific treatments. (Click here for more
You may also be interested in...
Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs
NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.